“Brodalumab Provides Rapid Onset of Therapeutic Response for Patients With Moderate-to-Severe Psoriasis” (2023) SKIN The Journal of Cutaneous Medicine, 7(2), p. s133. doi:10.25251/skin.7.supp.133.